In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease Dr. Crew worries that people are dying or losing limbs unnecessarily from this deadly disease because they or their doctors aren't aware that a new treatment is available


In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease

Dr. Crew worries that people are dying or losing limbs unnecessarily from this deadly disease because they or their doctors aren't aware that a new treatment is available

PR Newswire

DALY CITY, Calif., July 24, 2014 /PRNewswire/ -- The National Necrotizing Fasciitis Foundation (NNFF) today is calling attention to an interview on RadioMD with Dr. John Crew, Medical Director of the Advanced Wound Care Center at Seton Medical Center in Daly City, California. The subject: A new treatment for deadly flesh-eating disease, or necrotizing fasciitis.

Dr. John Crew, the Medical Director of Seton Medical Center’s Advanced Wound Care facility in the San Francisco
               Bay Area, was recently featured on RadioMD's "Staying Well" program. Dr. Crew provided information on his treatment
               for flesh eating disease that uses NovaBay’s NeutroPhase, a non-antibiotic wound cleanser, to save the lives and limbs
               of his patients.

"As Dr. Crew said in the interview, doctors are having great success with a new treatment that Dr. Crew has pioneered," said Jacqueline Roemmele, executive director of the NNFF. "But many doctors and patients aren't yet aware that this treatment exists. So tragically, victims continue to lose their lives or have limbs amputated because of this terrible disease. We're doing everything we can to spread the message that there is a medical advance that really will help patients and their families. I am hopeful this RadioMD interview will help to get the word out."

RadioMD is a talk show aimed at bringing accurate, timely information to consumers. On July 21, RadioMD's Melanie Cole talked with Dr. John Crew about necrotizing fasciitis, a disease that kills up to 20 percent of its victims even with aggressive treatment.

As Dr. Crew explained in the interview, flesh-eating disease has been known since the age of Hippocrates. It starts when bacteria get under the skin and start to spread. The body tries to fight the infection, but toxins from the bacteria and the reaction of the body's own immune system together eat away tissue. "The body starts digesting itself," said Dr. Crew.

The traditional treatment is to kill the bacteria with antibiotics and "to cut until you get rid of all the areas affected," Dr. Crew explained. But because the tissue can die so fast, "people lost arms, legs or their life very quickly."

In the new treatment developed by Dr. Crew, doctors irrigate the wound with NeutroPhase, a product from Emeryville, California biopharmaceutical company NovaBay Pharmaceuticals (NYSE: NBY). NeutroPhase contains hypochlorous acid, "the substance that God created inside white blood cells to kill bacteria," said Dr. Crew.

After Dr. Crew saved the arm and life of the first patient he treated, he realized the potential of NeutroPhase.  Dr. Crew knew that in laboratory testing it has been shown to kill a broad spectrum of bacteria and also to neutralize the toxins that are known to exist in the tissues of NF patients."  

He's now overseen the successful treatment of more than two dozen victims, and he's anxious to make people aware of the advance and to convince other doctors to use it. "We've had great success when doctors treat patients in the right way, but terrible success when they won't use it."

"It's extremely important to recognize the disease for what it is, and that there is something available to treat it," he added. "We will send the material anywhere if your doctor will use it."

Jacqueline Roemmele

Executive Director

National Necrotizing Fasciitis Foundation

jroemmele@aol.com  

908-422-7744

Photo - http://photos.prnewswire.com/prnh/20140724/130042

SOURCE National Necrotizing Fasciitis Foundation

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here